Evidence map›Paper›PMID 26347077›Full record

ArticleInternational urology and nephrology2015

Patient preferences for treating refractory overactive bladder in the UK.

Hashim Hashim, Kathleen Beusterien, John F P Bridges, Kaitlan Amos, Linda Cardozo

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05519072 (Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA Treatment of Overactive Bladder), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05519072 phase4recruitingnot on this mapstarted 2022, after this paper: background citation

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA Treatment of Overactive Bladder: a Randomized Controlled Trial

TypeinterventionalSponsorAtlantic Health SystemRan2022 to 2024Enrolled140ConditionsAntibiotic ProphylaxisArmsNitrofurantoin
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Review
  17. Article
  18. Overactive bladder.F1000Research · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Hashim HashimBristol Urological Institute, Bristol, UK. h.hashim@gmail.com.
Kathleen BeusterienORS Health, 3523 Albemarle St. NW, Washington, DC, 20008, USA. Kathy.beusterien@orshealth.com.
John F P BridgesDepartment of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. jbridges@jhsph.edu.
Kaitlan AmosORS Health, Andover, MA, USA. kaitlan.amos@orshealth.com.
Linda CardozoUrogynaecology Department, King's College Hospital, London, UK. Linda@lindacardozo.co.uk.
Albemarle (United States) · USAndover Eye Associates · USAt Bristol · GBJohns Hopkins University · USKing's College Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate patient preferences for refractory overactive bladder (OAB) treatments: sacral neuromodulation (SNM), onabotulinum toxin A (Botox(®)), and percutaneous tibial nerve stimulation (PTNS). MATERIALS AND

methodsA cross-sectional Web survey was conducted with UK idiopathic OAB patients, recruited by a market research company. Preference was explored using direct questioning, comparing SNM, Botox, and PTNS, and via best-worst scaling (BWS). In BWS, patients prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks, identifying the attribute they considered best and worst in each task. The attributes were those that were identified by patients in previous qualitative interviews as influential in treatment selection. BWS scores for each attribute, ranging from 1.0 (most favourable) to -1.0 (most unfavourable), were calculated based on the rates they were identified as best and as worst. To identify attributes that may influence treatment choice, BWS scores were compared among patients based on their most preferred treatment using analyses of variance; pairwise differences were assessed using Tukey's multiple comparisons test.

resultsThe study population (N = 139) was 77 % female, had a mean age of 49 years, and were diagnosed a mean of 6.1 years ago. All 13 attribute BWS scores were viewed positively (score > 0.0) or negatively (score < 0.0). Among the 127 (91 %) of patients who had experience with OAB medication only, most (≥80 %) were willing to try each of the three treatments; 57, 34, and 9 % most preferred PTNS, SNM, and Botox, respectively. Preferences for the attributes differed based on which treatment that patients preferred. Specifically, patients preferring SNM (PS) favoured 'implanted device in upper buttock' more than those preferring PTNS (PP) or Botox (PB). Compared to PB, PS also favoured 'sends signals between bladder and brain to help restore bladder function' and 'test phase'. PB favoured 'Botox (botulinum toxin) treatment' and 'treatment procedure delivered through the urethra' more than PS and PP. PP favoured the following more than PS and PB: 'needle inserted into ankle', 'minimal side effects' and 'treatment requires repeated visits over time'.

conclusionThis study identified specific characteristics of specialized therapies for refractory OAB that may significantly influence patient preferences, which may be used to help inform treatment decision-making.

Indexed as

Implantable NeurostimulatorsTranscutaneous Electric Nerve StimulationAcetylcholine Release InhibitorsAdultBotulinum Toxins, Type ACross-Sectional StudiesFemaleHealth Care SurveysHumansLumbosacral PlexusMaleMiddle AgedPatient PreferencePerceptionRetreatmentTibial NerveAcetylcholine Release InhibitorsBotulinum Toxins, Type ABotoxOnabotulinum toxin APatient preferencesPercutaneous tibial nerve stimulationRefractory OAB treatmentSacral neuromodulation

Identifiers

PMID26347077
OpenAlexW1418815612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.